Current drugs for Alzheimer’s disease (AD) can delay disease progress but cannot cure the disease. As general practitioners or family physicians may not be able to confidentl\ measure the exact symptom changes, they oÑ–en continue current prescriptions, which can lead to a waste of medical expenditures. Нe number of patients with AD is rapidly growing in Japan, and the costs for the treatment and patient care will be a heavy social burden. Нe cost-benefit analysis for treatment and care is therefore important for AD. Patients’ QOL must be properly measured for this purpose, and many previous studies have measured QOL using EQ-5D-3L or EQ-5D-5L for patients with dementia. EQ-5D was developed as a self-rating scale, but many studies have questioned the validity of self-rating for Alzheimer’s disease patients.